Institute of Biotechnology and Microbiology, Bacha Khan University, Charsadda, Pakistan.
Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, Florida, USA.
J Biomol Struct Dyn. 2023 Dec;41(20):10859-10868. doi: 10.1080/07391102.2022.2158942. Epub 2022 Dec 19.
In 2022, the ongoing multi-country outbreak of monkeypox virus-now occurring outside Africa, too is a global health concern. Monkeypox is a zoonotic virus, which causes disease mainly in animals, and then it is transferred to humans. Recently, in the monkeypox epidemic, a large number of human cases emerged while the global health community worked to tackle the outbreak and save lives. Herein, a multi-epitope-based vaccine is designed against monkeypox virus using two surface-associated proteins: MPXVgp002 accession number > YP_010377003.1 and MPXVgp008 accession number > YP_010377007.1 proteins. These proteins were utilized for B- and T-cell epitopes prediction. The epitopes were further screened, and the screen filtered KCKDNEYRSR, RSCNTTHNR, and RTRRETGAS with the antigenicity scores of 0.5279, 0.5604, and 0.7628, respectively. Overall, the epitopes can induce immunity in 99.74% population of the world. Further, GPGPG linkers were used for joining the epitopes and EAAAK linker was used for adjuvant attachment. It has a three-dimensional structure modelled for retaining the structural stability. Three pairs of amino acid residues that were able to make disulfide bonds were chosen: Gly1-Ser82, Cys7-Tyr10, and Phe51-Ile55. Molecular docking of vaccine was done with toll-like receptors, viz., 2, 3, 4, and 8 immune cell receptors. The docking results revealed that the vaccine as potential molecule due to its better binding affinity with toll-like receptors 2, 3, 4 and 8. Top complex in docking in with each receptor was selected based on lowest energy scores- -888.7 kcal/mol (TLR-2), -976.3 kcal/mol (TLR-3), -801.9 kcal/mol (TLR-4), and -955.4 kcal/mol (TLR-4)-were subjected to simulation. The docked complexes were evaluated in 500 ns of MD simulation. Throughout the simulation time, no significant deviation occurred. This confirmed that the vaccine as potential vaccine candidate to interact with immune cell receptors. This interaction is important for the immune system activation. In conclusion, the proposed vaccine construct against monkeypox could induce an effective immune response and speed up the vaccine development process. However, the study is completely based on the computational approach, hence, the experimental validation is required.Communicated by Ramaswamy H. Sarma.
2022 年,正在多国爆发的猴痘病毒——现在也发生在非洲以外的地区——也是全球关注的健康问题。猴痘是一种人畜共患病毒,主要在动物中引起疾病,然后传播给人类。最近,在猴痘疫情中,大量人类病例出现,而全球卫生界则努力应对疫情并拯救生命。在此,我们设计了一种基于多表位的疫苗,针对猴痘病毒使用两种表面相关蛋白:MPXVgp002 登录号 > YP_010377003.1 和 MPXVgp008 登录号 > YP_010377007.1 蛋白。这些蛋白被用于 B 细胞和 T 细胞表位预测。进一步筛选了表位,筛选出抗原性评分分别为 0.5279、0.5604 和 0.7628 的 KCKDNEYRSR、RSCNTTHNR 和 RTRRETGAS。总的来说,这些表位可以诱导世界上 99.74%的人口产生免疫。此外,还使用 GPGPG 接头连接表位,使用 EAAAK 接头连接佐剂。它具有三维结构模型,以保持结构稳定性。选择了三个能够形成二硫键的氨基酸残基对:Gly1-Ser82、Cys7-Tyr10 和 Phe51-Ile55。对疫苗与 Toll 样受体(TLR)2、3、4 和 8 种免疫细胞受体进行了分子对接。对接结果表明,由于与 Toll 样受体 2、3、4 和 8 的结合亲和力更好,该疫苗是一种潜在的分子。根据最低能量评分——TLR-2 为-888.7 kcal/mol、TLR-3 为-976.3 kcal/mol、TLR-4 为-801.9 kcal/mol 和 TLR-4 为-955.4 kcal/mol——选择了每个受体的最佳对接复合物,并进行了模拟。对接复合物在 500 ns 的 MD 模拟中进行了评估。在整个模拟时间内,没有出现明显的偏差。这证实了疫苗作为潜在疫苗候选物与免疫细胞受体相互作用的能力。这种相互作用对于激活免疫系统很重要。总之,针对猴痘的建议疫苗构建体可以诱导有效的免疫反应,并加速疫苗开发过程。然而,这项研究完全基于计算方法,因此需要进行实验验证。由 Ramaswamy H. Sarma 传达。